<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8BCD7228-A8CE-4BEA-9B7E-3B061A3E753B"><gtr:id>8BCD7228-A8CE-4BEA-9B7E-3B061A3E753B</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>R</gtr:otherNames><gtr:surname>Bloom</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FE021972%2F1"><gtr:id>8056A160-C6F5-4244-9DCA-42CA325B74ED</gtr:id><gtr:title>The role of NPY in the DMH in energy balance</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/E021972/1</gtr:grantReference><gtr:abstractText>Neuropeptide Y (NPY) is a substance occurring naturally in the brain. The hypothalamus is one of the most important brain regions involved in the regulation of appetite. When injected directly into the hypothalamus, NPY causes dramatic hunger and obesity. NPY is found in two areas of the hypothalamus, the ARC and the DMH. ARC NPY powerfully stimulates appetite. However, the role of NPY in the DMH in the regulation of appetite is unknown. In obesity, NPY levels are decreased in the ARC but increased in the DMH. My pilot data suggests NPY in the DMH acts to reduce body weight. I will therefore determine the role of NPY in the DMH in the control of food intake and body weight. I hypothesise that NPY in the DMH is important in the regulation of appetite. I will investigate this by increasing and decreasing NPY in the DMH using gene therapy techniques. I will then study the effects of these alterations by measuring food intake, body weight and energy expenditure. These studies offer a possible exciting new insight into the control of appetite and body weight.</gtr:abstractText><gtr:technicalSummary>The central dogma of hypothalamic appetite control proposes that neuropeptide Y (NPY) is exclusively an appetite stimulating factor. Intracerebroventricular (ICV) injection of NPY potently stimulates appetite. In obesity NPY is greatly reduced in the arcuate nucleus (ARC). However, in the dorsomedial hypothalamus (DMH) NPY is elevated in obesity. In a pilot study I have over expressed NPY in the DMH and observed a major chronic decrease in weight. Thus, there may be two NPY circuits with opposing effects on energy balance. I now propose to establish the role of DMH NPY in causing negative energy balance. I hypothesise that NPY in the DMH acts to reduce fat stores. I will test this hypothesis using the gene transfer vector recombinant adeno-associated virus (rAAV) to alter NPY expression in the DMH of male Wistar rats. I will initially determine the time course for changes in NPY mRNA expression within the DMH in rats fed a high fat diet. I will then use rAAV encoding NPY to over express NPY in the DMH and determine the effects on food intake, body weight and energy expenditure. Two approaches will be used to determine the physiological role of DMH NPY in the regulation of energy balance. Firstly I will use rAAV encoding antisense NPY (rAAV-NPY-AS) to prevent the rise in DMH NPY expression seen following high fat feeding. Secondly, I will use rAAV-NPY-AS to attenuate the high fat diet induced increase in DMH NPY after it has occurred. Food intake, body weight and energy expenditure will be measured. At the end of each study, body composition will be measured by both MRI and dissolution followed by chemical analysis. This work will determine the role of DMH NPY in the regulation of energy balance.</gtr:technicalSummary><gtr:fund><gtr:end>2010-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2007-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>272603</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Neuropeptide Y (NPY) is a substance occurring naturally in the brain. The hypothalamus is one of the most important brain regions involved in the regulation of appetite. When injected directly into the hypothalamus, NPY causes dramatically increased hunger and results in obesity and this orexigenic action of NPY has become standard dogma. 

However, NPY is found in two areas of the hypothalamus, the ARC and the DMN. While ARC NPY powerfully stimulates appetite, the role of NPY in the DMN in the regulation of appetite is unknown. Surprisingly, although NPY is down-regulated in the ARC in ob/ob obese mice, it is up-regulated in the DMN suggesting the role in this nucleus is opposite to that in the ARC. To test this hypothesis we used a gene therapy approach. We found that increasing expression of NPY in the DMN decreased food intake and weight gain. The same results were achieved following acute injection of NPY into the DMN; food intake was decreased rather than increased (as it is when NPY is injected into other areas). These findings may explain other studies that have inactivated the NPY gene in mice and found they become obese rather than lose weight as expected. This work has reinforced the differential role of particular neuropeptides in different circuits and thrown light on why global NPY knock-out animals and administration of systemic antagonists of NPY unexpectedly produce a variable phenotype.</gtr:description><gtr:firstYearOfImpact>2010</gtr:firstYearOfImpact><gtr:id>56DFB6B9-BF5B-4A2C-8716-BCFA28B66B10</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>5461ee8f21d372.11257325</gtr:outcomeId><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>22FBDAB0-1445-4F74-90DE-C0AC1BF77B5C</gtr:id><gtr:title>The hyperphagic effect of ghrelin is inhibited in mice by a diet high in fat.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18ea5d6dc21306abb71f083882e847c6"><gtr:id>18ea5d6dc21306abb71f083882e847c6</gtr:id><gtr:otherNames>Gardiner JV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>5450d45f7d7817.24759855</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51249C94-3C3F-4AD9-9EC5-45906EAE5D3C</gtr:id><gtr:title>Co-administration of SR141716 with peptide YY3-36 or oxyntomodulin has additive effects on food intake in mice.</gtr:title><gtr:parentPublicationTitle>Diabetes, obesity &amp; metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bd0d858698e38f63dd6f77194ef0cf9"><gtr:id>7bd0d858698e38f63dd6f77194ef0cf9</gtr:id><gtr:otherNames>White NE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1462-8902</gtr:issn><gtr:outcomeId>5450d45dd287c4.07408422</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BEBC107F-1092-46D2-A732-1CBDF42E72AA</gtr:id><gtr:title>Coordinated changes in energy intake and expenditure following hypothalamic administration of neuropeptides involved in energy balance.</gtr:title><gtr:parentPublicationTitle>International journal of obesity (2005)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/729e284d36dcb825ed1241f86b1599c1"><gtr:id>729e284d36dcb825ed1241f86b1599c1</gtr:id><gtr:otherNames>Semjonous NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0307-0565</gtr:issn><gtr:outcomeId>2AD22D57699</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6721777F-12C0-4685-AD57-2F8A29CA5016</gtr:id><gtr:title>Cerebellin1 is a novel orexigenic peptide.</gtr:title><gtr:parentPublicationTitle>Diabetes, obesity &amp; metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18ea5d6dc21306abb71f083882e847c6"><gtr:id>18ea5d6dc21306abb71f083882e847c6</gtr:id><gtr:otherNames>Gardiner JV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1462-8902</gtr:issn><gtr:outcomeId>5450d45fdd0292.34533480</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E52BD154-5404-4CFF-8F15-51ED33AE1B75</gtr:id><gtr:title>Arcuate nucleus glucokinase and dietary glucose intake.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/417d43a7089aa342f399b24e0f14fc1c"><gtr:id>417d43a7089aa342f399b24e0f14fc1c</gtr:id><gtr:otherNames>Ma Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>58b9d7a42be818.52869338</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AEDC481-4989-4B97-9EDB-7FE60B386FD1</gtr:id><gtr:title>The thyroid hormone derivative 3-iodothyronamine increases food intake in rodents.</gtr:title><gtr:parentPublicationTitle>Diabetes, obesity &amp; metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8445db1be2f56784f9ea425402b79e11"><gtr:id>8445db1be2f56784f9ea425402b79e11</gtr:id><gtr:otherNames>Dhillo WS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1462-8902</gtr:issn><gtr:outcomeId>5450d45eb6b026.98186614</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C4B4D45-926D-43AA-A2B1-4EEB5B933C92</gtr:id><gtr:title>Hypothalamic mapping of orexigenic action and Fos-like immunoreactivity following relaxin-3 administration in male Wistar rats.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69ac71aa010bea0adc6be6d0e11cd6b9"><gtr:id>69ac71aa010bea0adc6be6d0e11cd6b9</gtr:id><gtr:otherNames>McGowan BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0193-1849</gtr:issn><gtr:outcomeId>5450d45da3bfd4.13872118</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A081F621-C841-44F3-A0A1-8F72489A24FD</gtr:id><gtr:title>Overexpression of CART in the PVN increases food intake and weight gain in rats.</gtr:title><gtr:parentPublicationTitle>Obesity (Silver Spring, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f73e3beb2f837cd6fab433940d23dba9"><gtr:id>f73e3beb2f837cd6fab433940d23dba9</gtr:id><gtr:otherNames>Smith KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1930-7381</gtr:issn><gtr:outcomeId>5450d45ee55cc7.95062252</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>896CE754-307D-4F94-BBD0-043B7CB7DC83</gtr:id><gtr:title>Prokineticin 2 is a hypothalamic neuropeptide that potently inhibits food intake.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18ea5d6dc21306abb71f083882e847c6"><gtr:id>18ea5d6dc21306abb71f083882e847c6</gtr:id><gtr:otherNames>Gardiner JV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>5450d45f4f9c84.30291365</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BA8587D-CBD8-4236-8089-431527984AE9</gtr:id><gtr:title>Peripheral and central administration of xenin and neurotensin suppress food intake in rodents.</gtr:title><gtr:parentPublicationTitle>Obesity (Silver Spring, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2dc23dfe4488ad7bd3bcecfab483bee9"><gtr:id>2dc23dfe4488ad7bd3bcecfab483bee9</gtr:id><gtr:otherNames>Cooke JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1930-7381</gtr:issn><gtr:outcomeId>5460e58589b490.85522019</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CC0F1F5-26E5-44F7-851F-D63299EBEDE1</gtr:id><gtr:title>Accurate measurement of body weight and food intake in environmentally enriched male Wistar rats.</gtr:title><gtr:parentPublicationTitle>Obesity (Silver Spring, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9252f8619835fb0700badaa10388e447"><gtr:id>9252f8619835fb0700badaa10388e447</gtr:id><gtr:otherNames>Beale KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1930-7381</gtr:issn><gtr:outcomeId>pm_15139_29_21233804</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D586DC72-0192-4D90-867B-DC9AB0E8B54E</gtr:id><gtr:title>Increased energy expenditure in gastric bypass rats is not caused by activated brown adipose tissue.</gtr:title><gtr:parentPublicationTitle>Obesity facts</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac2bd9e5e82e9a66e3bdeac649f848a3"><gtr:id>ac2bd9e5e82e9a66e3bdeac649f848a3</gtr:id><gtr:otherNames>Hankir M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1662-4025</gtr:issn><gtr:outcomeId>pm_15139_29_22722324</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA4E1D81-4DFD-49AA-9CFB-5E233A38FC25</gtr:id><gtr:title>Mice with hyperghrelinemia are hyperphagic and glucose intolerant and have reduced leptin sensitivity.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/002144928c3e9bea7d312ce9854f9a4b"><gtr:id>002144928c3e9bea7d312ce9854f9a4b</gtr:id><gtr:otherNames>Bewick GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>5450d45f208aa7.44539451</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F646F61E-C656-4644-92F7-7BC562CC3D37</gtr:id><gtr:title>Alarin stimulates food intake and gonadotrophin release in male rats.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afba1051fb23369c05361a750d56025e"><gtr:id>afba1051fb23369c05361a750d56025e</gtr:id><gtr:otherNames>Boughton CK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>5450d45fae0673.69432126</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3020B5E-E2B2-49F2-B7F0-9987C89B50AD</gtr:id><gtr:title>Relaxin-3 stimulates the hypothalamic-pituitary-gonadal axis.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69ac71aa010bea0adc6be6d0e11cd6b9"><gtr:id>69ac71aa010bea0adc6be6d0e11cd6b9</gtr:id><gtr:otherNames>McGowan BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0193-1849</gtr:issn><gtr:outcomeId>5450d45e48d702.50513731</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1612E95F-8583-4B50-8639-CB64044934E3</gtr:id><gtr:title>Central and peripheral administration of human relaxin-2 to adult male rats inhibits food intake.</gtr:title><gtr:parentPublicationTitle>Diabetes, obesity &amp; metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69ac71aa010bea0adc6be6d0e11cd6b9"><gtr:id>69ac71aa010bea0adc6be6d0e11cd6b9</gtr:id><gtr:otherNames>McGowan BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1462-8902</gtr:issn><gtr:outcomeId>5450d4601e7039.69879138</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F611040F-8254-4BE7-904F-A111A368BC54</gtr:id><gtr:title>Intracerebroventricular administration of vasoactive intestinal peptide inhibits food intake.</gtr:title><gtr:parentPublicationTitle>Regulatory peptides</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ce37edb20d795e3e6a4e02939177411"><gtr:id>8ce37edb20d795e3e6a4e02939177411</gtr:id><gtr:otherNames>Ghourab S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0167-0115</gtr:issn><gtr:outcomeId>pm_15139_29_21802451</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/E021972/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>